The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 171, 160-166
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research articleJournal of Cardiothoracic Surgery, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilateThrombosis and Haemostasis, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by α2‐macroglobulin‐thrombinJournal of Thrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrenceBritish Journal of Haematology, 2007
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulabilityPathophysiology of Haemostasis and Thrombosis, 2002